NCT00575406 - Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Rituximab

i.v., 375 mg/m2, d0 or d1 of each treatment cycle

DRUG

Cyclophosphamide

i.v., 750 mg/m2, d1 of each treatment cycle

DRUG

Doxorubicin

i.v., 50 mg/m2, d1 of each treatment cycle

DRUG

liposomal Doxorubicin

i.v., 50 mg/m2, d1 of each treatment cycle

DRUG

Vincristin

i.v., 2mg, d1 of each treatment cycle

DRUG

Prednisolone

p.o., 100mg, d1 - d5 of each treatment cycle

Trial Locations (10)

A-6806

Landeskrankenhaus Feldkirch, Feldkirch

A-6020

Universitaetsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck

A-8700

A.ö. Landeskrankenhaus Leoben, Leoben

A-4010

Krankenhaus d. Barmherzigen Schwestern Linz, Linz

Krankenhaus der Elisabethinen Linz, Linz

A-4020

Krankenhaus der Stadt Linz, Linz

A-5020

Universitaetsklinik f. Innere Medizin III, Salzburg

A-1090

AKH Wien / Haematologie u. Haemostaseologie, Vienna

A-1140

Hanusch Krankenhaus, Vienna

A-4600

Klinikum Kreuzschwestern Wels GmbH, Wels

All Listed Sponsors

lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER